- In March 2025, AGC Biologics launched a dedicated Cell and Gene Technologies Division to enhance support for developers of cell and gene therapies. The new division provides expanded capacity, scientific expertise, and specialized CDMO services across facilities in Milan, Longmont, Colorado, and Yokohama, Japan. This initiative aims to accelerate the development and manufacturing of advanced therapies globally
- In October 2023, Aurion Biotech initiated a phase 1/2 clinical trial in the U.S. to evaluate its cell therapy aimed at treating corneal edema. This study marks a significant advancement in exploring innovative treatment options for this eye condition. The trial's progression will be closely monitored as it seeks to demonstrate the therapy's safety and efficacy in patients
- In October 2023, Nkarta, Inc. received FDA approval for its Investigational New Drug (IND) application to study NKX019, an allogeneic CAR NK cell therapy targeting CD19. This therapy aims to provide a novel treatment option for lupus nephritis, a challenging autoimmune condition. The approval marks a crucial step in advancing NKX019 towards clinical trials, where its effectiveness and safety will be assessed
- In June 2023, Vertex Pharmaceuticals Incorporated partnered with Lonza to establish a joint venture aimed at enhancing the production of Vertex's investigational stem cell therapies. This collaboration specifically targets treatments for Type 1 Diabetes (T1D), concentrating on the clinical trial programs VX-880 and VX-264. The initiative is expected to streamline manufacturing processes and support the advancement of these promising therapies
- In May 2023, Johnson & Johnson entered into a global collaboration and licensing agreement with Cellular Biomedicine Group to co-develop advanced CAR-T therapies. This partnership aims to innovate and enhance the effectiveness of CAR-T treatments, reflecting both companies' commitment to advancing cancer therapies. The collaboration is expected to accelerate the development of these next-generation therapies in the oncology space
- In March 2023, Adaptimmune Therapeutics plc and TCR2 Therapeutics announced a strategic partnership aimed at establishing a leading cell therapy organization focused on treating solid tumors. This alliance is designed to leverage each company's expertise and resources to advance innovative therapies in this challenging area of oncology. The collaboration reflects a shared commitment to improving
